First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts
Authors
Keywords
-
Journal
ESMO Open
Volume 6, Issue 1, Pages 100030
Publisher
Elsevier BV
Online
2021-01-15
DOI
10.1016/j.esmoop.2020.100030
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk of COVID-19 for cancer patients
- (2020) Yang Xia et al. LANCET ONCOLOGY
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) Bernard Escudier et al. ANNALS OF ONCOLOGY
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
- (2019) Brian I Rini et al. LANCET ONCOLOGY
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
- (2017) Hans J. Hammers et al. JOURNAL OF CLINICAL ONCOLOGY
- Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms
- (2016) C. Rothermundt et al. WORLD JOURNAL OF UROLOGY
- Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes
- (2015) C. Rothermundt et al. ONCOLOGIST
- Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial
- (2014) Amikumar Mehta et al. Future Oncology
- Objective consensus from decision trees
- (2014) Paul Martin Putora et al. Radiation Oncology
- Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials
- (2013) D. Y. C. Heng et al. ANNALS OF ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started